In 1976, Albert Einstein Cancer Center researchers identified the mechanism of action of Taxol, one of the most significant cancer treatment drugs ever developed.

In 1992, the U.S. (FD) approved Bristol-Myers Squibb Company’s Taxol for the treatment of advanced carcinoma of the ovary and as adjuvant treatment of node-positive breast cancer.